Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 16.77% for the trailing four quarters.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the fourth quarter of 2018. Our consensus called for EPS of $1.83, and the company reported EPS of $2.14.
Revenue: Revenues, also, beat expectations. Alexion posted revenues of $1.128 billion, compared to our consensus estimate of $1.06 billion.
Key Stats: Soliris sales increased 23% in the quarter to $976.7 million. During the quarter the FDA approved Ultomiris for adults with PNH. Applications for approval in the European Union (EU) and Japan are currently under review for the same indication.
2019 Guidance: The company expects earnings per share to be in the range $9.10 to $9.30. It projects revenues to be in the range of $4.63 to $4.70 billion. The Zacks Consensus Estimate for earnings for 2019 was $8.78 per share while for sales it was $4.76 billion. Revenues for Soliris and Ultomiris are expected in the $3.97-$4.02 billion range.
Share Price Impact: Share price increased 6.1% in pre-market trading.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Image: Bigstock
Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 16.77% for the trailing four quarters.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the fourth quarter of 2018. Our consensus called for EPS of $1.83, and the company reported EPS of $2.14.
Revenue: Revenues, also, beat expectations. Alexion posted revenues of $1.128 billion, compared to our consensus estimate of $1.06 billion.
Key Stats: Soliris sales increased 23% in the quarter to $976.7 million. During the quarter the FDA approved Ultomiris for adults with PNH. Applications for approval in the European Union (EU) and Japan are currently under review for the same indication.
2019 Guidance: The company expects earnings per share to be in the range $9.10 to $9.30. It projects revenues to be in the range of $4.63 to $4.70 billion. The Zacks Consensus Estimate for earnings for 2019 was $8.78 per share while for sales it was $4.76 billion. Revenues for Soliris and Ultomiris are expected in the $3.97-$4.02 billion range.
Share Price Impact: Share price increased 6.1% in pre-market trading.
Alexion Pharmaceuticals, Inc. Price and EPS Surprise
Alexion Pharmaceuticals, Inc. Price and EPS Surprise | Alexion Pharmaceuticals, Inc. Quote
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>